EGFR and astrocytoma (excluding glioblastoma): A recent consensus from the cIMPACT-NOW consortium has proposed that grade II and III IDHwt astrocytomas harboring epidermal growth factor receptor (EGFR) amplifications, and/or combining whole chromosome 7 gain and whole chromosome 10 loss (+ 7/ − 10), and/or harboring telomerase reverse transcriptase (TERT) promoter mutations should be considered true GBMs, given their poor survival prospects9.